GSK-3 Inhibitor Elraglusib Enhances Tumor-Infiltrating Immune Cell Activation in Tumor Biopsies and Synergizes with Anti-PD-L1 in a Murine Model of Colorectal Cancer

Mostrar otras versiones (1)

Glycogen synthase kinase-3 (GSK-3) is a serine/threonine kinase that has been implicated in numerous oncogenic processes. GSK-3 inhibitor elraglusib (9-ING-41) has shown promising preclinical and clinical antitumor activity across multiple tumor types. Despite promising early-phase clinical trial re...

Descripción completa

Detalles Bibliográficos
Autores principales: Huntington, Kelsey E., Louie, Anna D., Srinivasan, Praveen R., Schorl, Christoph, Lu, Shaolei, Silverberg, David, Newhouse, Daniel, Wu, Zhijin, Zhou, Lanlan, Borden, Brittany A., Giles, Francis J., Dooner, Mark, Carneiro, Benedito A., El-Deiry, Wafik S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10342141/
https://www.ncbi.nlm.nih.gov/pubmed/37446056
http://dx.doi.org/10.3390/ijms241310870

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10342141/
https://www.ncbi.nlm.nih.gov/pubmed/37446056
http://dx.doi.org/10.3390/ijms241310870

Ejemplares similares